| Literature DB >> 36046827 |
Ling Lu1, Bei Chen2,3, Yumeng Xu2, Xinyi Zhang2, Longtao Jin1, Hui Qian2, Yi Wang4, Zhao Feng Liang2.
Abstract
Gastric cancer (GC) is a malignant cancer of the digestive tract and is a life-threatening disease worldwide. Ferroptosis is a newly discovered form of regulated cell death, which involves the accumulation of iron-dependent lipid peroxides. It has been found that ferroptosis plays an important regulatory role in the occurrence, development, drug resistance, and prognosis of GC. Non-coding RNAs (ncRNAs) play a critical role in the occurrence and progression of a variety of diseases including GC. In recent years, the role of ferroptosis and ferroptosis-related ncRNAs (miRNA, lncRNA, and circRNA) in the occurrence, development, drug resistance, and prognosis of GC has attracted more and more attention. Herein, we briefly summarize the roles and functions of ferroptosis and ferroptosis-related ncRNAs in GC tumorigenesis, development, and prognosis. We also prospected the future research direction and challenges of ferroptosis and ferroptosis-related ncRNAs in GC.Entities:
Keywords: ferroptosis; function; gastric cancer; mechanisms; noncoding RNA
Year: 2022 PMID: 36046827 PMCID: PMC9421149 DOI: 10.3389/fphar.2022.902302
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Overview of the role of ferroptosis-related miRNAs in GC.
| MiRNA | Expression status | Relationship with autophagy | Target | Type of biomarker | References |
|---|---|---|---|---|---|
| miR-522 | Upregulated | Inhibited ferroptosis | ALOX15 | Chemo- resistance |
|
| miR-375 | Upregulated | Triggered ferroptosis | SLC7A11 | Stemness of GC |
|
| miR-103a-3p | Downregulated | Promoted ferroptosis | GLS2 | Development and prognosis |
|
| miR-489-3p | Upregulated | Enhanced ferroptosis | SLC7A11 | Development and treatment |
|
| miR-125b-5p | Upregulated | Enhanced ferroptosis | STAT3 | Development |
|
| miR-4715-3p | Downregulated | Enhanced ferroptosis | AURKA/GPX4 | Development and prognosis |
|
Overview of the role of ferroptosis-related lncRNAs in GC.
| LncRNA | Expression status | Relationship with autophagy | Target | Type of biomarker | References |
|---|---|---|---|---|---|
| lncBDNF-AS | Upregulated | Inhibited ferroptosis | WDR5/FBXW7 | Development |
|
| lncLASTR | Upregulated | Inhibited ferroptosis | GPX4 | Occurrence, development, and prognostic |
|
| lncFERO | Upregulated | Inhibited ferroptosis | hnRNPA1/SCD1 | Development, resistance, and treatment |
|
| lncA2M-AS1, C2orf27A, and ZNF667-AS1 | Upregulated | Inhibited ferroptosis | hub FRGs (MYB, PSAT1, TP53, and LONP1) | Treatment and prognostic |
|
| 17 ferroptosis-related lncRNAs | Differential expression | Treatment and prognostic |
| ||
| 20 ferroptosis-related lncRNAs | Differential expression | Diagnostic and prognostic |
| ||
| AP000695.2, AL365181.3, and LINC01615 | Upregulated | Treatment and prognostic |
| ||
| AP003392.1, AC245041.2, AP001271.1, and BOLA3-AS1 | Expression correlated with clinical features | Treatment and prognostic |
| ||
| 17 ferroptosis-related lncRNAs | Differential expression | cytoskeleton, WNT and PI3K/mTOR | Development, treatment, and prognostic |
| |
| 10 ferroptosis-related lncRNAs | Differential expression | Prognostic and resistance |
| ||
| TMEM105, PVT1, LOC646588, FLJ22447, and DLEU1 | Differential expression | Treatment and prognostic |
|
FIGURE 1Ferroptosis plays an important role in GC and may regulate the occurrence and development of gastric cancer by interacting with related ncRNAs.